In ECHELON-2, adults with previously untreated CD30-expressing PTCL randomized to A + CHP (BV with cyclophosphamide, doxorubicin, and prednisone) versus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) demonstrated clinically meaningful improvements in 5-year OS (70.1% vs. 61.0%; HR, 0.72; 95% CI, 0.53–0.99) and 5-year PFS (51.4% vs. 43.0%; HR, 0.70; 95% CI, 0.53–0.91) [3]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.